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Betsy Ann Conway 
THE EFFECTS OF LAFORIN, MALIN, STBD1, AND PTG DEFICIENCIES ON HEART GLYCOGEN 
LEVELS IN POMPE DISEASE MOUSE MODELS 
 
Pompe disease (PD) is a rare metabolic myopathy characterized by loss of acid 
alpha-glucosidase (GAA), the enzyme responsible for breaking down glycogen to glucose 
within the lysosomes. PD cells accumulate massive quantities of glycogen within their 
lysosomes, and as such, PD is classified as a “lysosomal storage disease” (LSD). GAA-
deficient cells also exhibit accumulation of autophagic debris. Symptoms of severe 
infantile PD include extreme muscle weakness, hypotonia, and hypertrophic 
cardiomyopathy, resulting in death before one year of age.   
Certain LSDs are currently being successfully treated with enzyme replacement 
therapy (ERT), which involves intravenous infusion of a recombinant enzyme to 
counteract the endogenous deficiency.  ERT has been less successful in PD, however, 
due to ineffective delivery of the recombinant enzyme.  Alternatively, specific genes 
deletion may reduce lysosomal glycogen load, and could thus be targeted in PD therapy 
development. Absence of malin (EPM2B) or laforin (EPM2A) has been proposed to 
impair autophagy, which could reduce lysosomal glycogen levels.  Additionally, 
deficiency of Stbd1 has been postulated to disable lysosomal glycogen import.  
Furthermore, Ptg deficiency was previously reported to abrogate Lafora body formation 
and correct neurological abnormalities in Lafora disease mouse models and could have 
similar effects on PD pathologies.   
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 The goal of this study was to characterize the effects of homozygous disruption 
of Epm2a, Epm2b, Stbd1, and Ptg loci on total glycogen levels in PD mouse model heart 
tissue, as in severe infantile PD, it is accumulation of glycogen in the heart that results in 
fatal hypertrophic cardiomyopathy. Gaa-/- mice were intercrossed with Epm2a-/-, 
Epm2b-/-, Stbd1-/-, and Ptg-/- mice to generate wildtype (WT), single knockout, and 
double knockout mice.  The results indicated that Gaa-/- hearts accumulated up to 100-
fold more glycogen than the WT. These mice also displayed cardiac hypertrophy. 
However, deficiency of Epm2a, Epm2b, Stbd1, or PTG in the Gaa-/- background did not 
reveal changes of statistical significance in either heart glycogen or cardiac hypertrophy.  
Nevertheless, since total glycogen was measured, these deficiencies should not be 
discarded in future discussions of PD therapy, as increasing sample sizes and/or 
distinguishing cytosolic from lysosomal glycogen content may yet reveal differences of 
greater significance.  
 
 
         Peter J. Roach, Ph.D. 
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INTRODUCTION 
1. Glycogen Structure 
Glycogen is the large, branched polymer of glucose that is the primary form of 
energy storage in animals and fungi.  It is analogous to starch, the glucose storage unit 
in plants.  In the body’s fed state, insulin signals to cells to store excess glucose from the 
meal as glycogen.   The two primary sites of glycogen metabolism are the liver and 
skeletal muscle, though other tissues, including heart, adipose, brain, and kidney, are 
also capable of synthesizing glycogen (1).  Glycogen polymerization occurs between 
glucose monomers via α-1,4-glycosidic linkages, while branch points are introduced via 
α-1,6-glycosidic linkages (Figure 1).  As a polymer, glycogen has unbranched outer A-
chains and branched inner B-chains, each of which has approximately two branch points 
(Figure 2).  In totality, one molecule of glycogen consists of around 55,000 glucose 
residues, making for a molecular mass of ~107 kDa and a diameter of ~44 (nm) (2,3).   
Glycogen is primarily composed of glucose, but also contains small amounts of 
glucosamine and phosphate (4-6).  Glycogen phosphorylation has been more intently 
studied and has been accepted as an integral part of glycogen architecture.  Frequency 
of glycogen phosphorylation has been measured to be one phosphate for every ~650 
glucose residues in rabbit skeletal muscle glycogen and one for every ~2000 residues in 
mouse muscle glycogen (7,8).  The functions of glycogen phosphate and glucosamine 
have yet to be fully characterized; glycogen hyper- phosphorylation, however, has been 
shown to be associated with the neurodegenerative disorder, Lafora disease (see  
Introduction, section 4).  As glycogen molecules grow, they may accumulate chemical 
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Figure 1. Glycosidic Linkages in Glycogen.  Glycogen synthase catalyzes 
glycogen polymerization via α-1,4-glycosidic linkages.  Glycogen branching 
enzymes introduce branches every ~12 glucose units via α-1,6-glycosidic 
linkages.  The numbering of the carbons is shown for one of the glucose units.  
Adapted from “Lafora Disease: Mechanisms Involved in Pathogenesis” by 
Punitee Garyali, 2014. 
Figure 2. Glycogen Structure.   Glycogen organization depicted in a tiered 
model: the outer A-chains are unbranched, while the branched inner B-
chains have an average of two branches.  Glycogenin is represented as a 
black dot. Adapted from “Glycogen and its metabolism: some new 
developments and old themes” by Roach et al, 2012. 
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and structural abnormalities, which result in abnormal metabolism or solubility.  
Deposits of insoluble glycogen-like material have been observed in various neurological 
diseases.  
There are certain glycogen-associated proteins, which bind to glycogen, each  
other, and/or intracellular membranes; the complexes of these proteins along with 
glycogen are termed ‘glycogen particles’ (9-15) (Figure 3).   Known glycogen-associated 
proteins include the glycogen synthesis initiator enzyme, glycogenin, and glycogen 
metabolism-mediating enzymes, glycogen synthase, glycogen phosphorylase, glycogen-
branching enzyme, debranching enzyme, as well as various regulatory enzymes, such as 
phosphorylase kinase and the protein phosphatase 1G (PP1G) family (16).  The β-
subunit of AMP-activated protein kinase (AMPK), laforin, and starch-binding domain 
containing protein 1 (Stbd1) have also been shown to interact with glycogen via 
carbohydrate-binding module 20 domains (CBM20) (17-24). Functional roles in glycogen 
metabolism have been proposed for each of these glycogen-associated proteins. 
 
2. Glycogen Metabolism 
The polymerization of glycogen, called glycogenesis, requires glucose from either 
carbohydrate intake or gluconeogenic precursors (25).  Triggered by glucose uptake via 
glucose transporters (GLUTs) (26), glycogenesis (Figure 4) requires that glucose first be 
converted to glucose-6-phosphate (G6P).  Then, phosphoglucomutase (PGM) converts  
G6P to glucose-1-phosphate (G1P), which is in turn converted to uridine diphosphate 
glucose (UDPG) by UDP glucose phoshorylase (UGP).  The self-glycosylating protein, 
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Figure 3. Glycogen Particles.   The glycogen-associated proteins: the metabolic 
enzymes glycogenin (GN), glycogen synthase (GS), phosphorylase (Ph), and 
debranching enzyme (DBE); phosphatase type 1 catalytic subunit (PP1c); 
glycogen-targeting subunits RGL, GL, and PTG;  the protein kinases AMPK and 
phosphorylase kinase (Ph Kinase) ; Laforin; and Stbd1.  Capable of membrane 
anchoring are Stbd1, Ph Kinase, and RGL.  Adapted from “Glycogen and its 
metabolism: some new developments and old themes” by Roach et al, 2012. 
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Figure 4. Overview of Glycogen Metabolism.  GLUT, glucose transporter; HK 
hexokinase; G6Pase, glucose-6-phosphatase; PGM, phosphoglucomutase; 
UGP, UDP-glucose-phoshorylase; UGPPase, UDP-glucose-pyrophosphatase; 
GN, glycogenin; GS, glycogen synthase; BE, branching enzyme; AGL, 
debranching enzyme; GPh, glycogen phosphorylase; GAA, acid-α-glucosidase.  
Adapted from “Lafora Disease: Mechanisms Involved in Pathogenesis” by 
Punitee Garyali, 2014. 
6 
 
glycogenin (GN), begins glycogen polymerization by forming a short polymer of glucose 
units from UDPG (27-29). Glycogen synthase (GS) then continues to link glucose from 
UDPG via α-1,4 glycosidic bonds to the non-reducing end of the growing glycogen 
molecule.  This reaction is the rate-limiting step in glycogen synthesis.  Glycogen 
branching enzyme (GBE) introduces branch points via an α-1,6 glycosidic bond at the C6 
hydroxyl of glucose residue in the chain, giving an overall average branching frequency 
of one every twelve glucoses. 
Conversely, glycogen may also be broken back down to reform glucose via the 
process of glycogenolysis (Figure 4).  The cytosolic pathway involves three steps (Figure 
5).  First, in the rate-limiting step, a phosphoryl group substitution by glycogen 
phosphorylase (GPh) and its cofactor pyridoxal phosphate (PLP) breaks the position one 
bonds until just four glucose residues remain on the branch.  Second, the debranching 
enzyme (AGL) catalyzes the transfer and α-1,4-glycosidic linkage of these glucose units 
to the end of another branch of the glycogen polymer.  Third and finally, the C-terminus 
of AGL, which possesses amylo-1,6-glucosidase activity, removes the last remaining 
glucose residue.   
Hormonal regulation of glycogen metabolism is mediated by covalent 
modification of and allosteric ligand-binding to the primary glycogenic and 
glycogenolytic enzymes (Figure 6).  Following a meal, the increase in blood glucose 
signals to the pancreatic β-cells to release insulin into the blood stream.  Insulin binds  
allosterically to either of the two insulin receptor α-subunits, which causes a 
conformational change of the receptor and trans-phosphorylation of the two β- 
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Figure 5. Cytosolic Glycogenolyis.   Glycogen phosphorylase (GPh) breaks 
glycosidic linkages until just four glucose residues remain on the branch; 
debranching enzyme (AGL) transfers and these glucose units to the end of 
another branch; AGL, removes the last glucose residue.  Adapted from Berg 
JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 
2002. 
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Figure 6. Regulation of Glycogen Metabolism.   Schematic representation of the 
primary signaling pathways involved in glycogen metabolism.  PI3K, 
phosphatidylinositol kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, 
phosphatidylinositol-3,4,5-triphosphate; GSK3, glycogen synthase kinase 3; GS, 
glycogen synthase; PP1, protein phosphatase 1; PTG, protein targeting to glycogen; 
RGL, regulatory targeting subunit; GPh, glycogen phosphorylase; PKA, protein kinase 
A; cAMP, cyclic adenosine monophosphate.  Adapted from “Lafora Disease: 
Mechanisms Involved in Pathogenesis” by Punitee Garyali, 2014. 
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subunits.  The activated, phosphorylated cytosolic tyrosine kinase phosphorylates 
substrates that recruit SH2 domain-containing proteins, such as phosphatidylinositol-3-
kinase (PI3K).  Upon activation, PI3K converts membrane lipid, phosphatidylinositol-4,5-
bisphosphate (PIP2), to phosphatidylinositol-3,4,5-triphosphate (PIP3), which in turn 
activates protein kinase B (PKB, also known as AKT) via activation of PDK1.  Activated 
AKT inhibits glycogen synthase kinase-3 (GSK3) via phosphorylation, thereby preventing 
GSK3-mediated glycogen synthase inactivation (30).  Conversely, if activated, GSK3 
phosphorylates and inhibits glycogen synthase (1).  GS is activated by protein 
phosphatase type I (PP1) via dephosphorylation, which functions in conjunction with 
glycogen-targeting subunits, such as regulatory-targeting subunit (RGL or GM) and 
protein targeting to glycogen (PTG).   PP1 also regulates glycogen phosphorylase (GPh) 
via phosphorylation-mediated inactivation, thereby decreasing glycogen degradation.  
When glycogen is being degraded, GPh is activated by phosphorylase kinase, which is in 
turn activated by PKA and deactivated by PP1 and PP2A.  In short summary, pro-
glycogenic signaling via insulin facilitates glycogen synthesis by inhibiting GSK3, the 
inhibitor of GS, while pro-glycogenolytic signaling via epinephrine or glucagon facilitates 
glycogen breakdown by increasing cAMP-mediated PKA activity.  
 
3. Lysosomal Disposal of Glycogen and Pompe Disease 
While the primary means of glycogen degradation occurs via the cytosolic 
pathway, some glycogen is also transported into the lysosomes to be cleaved 
hydrolytically by the lysosomal enzyme acid α-glucosidase (GAA) (Figure 4).  Although 
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the lysosomal pathway is not the foremost mode of glycogen degradation, deficiency of 
GAA leads to a severe lysosomal storage disease known as Pompe disease (OMIM 
232300) (31).  The exact mode by which glycogen is transported into the lysosomes is 
unknown; it is thought, however, to involve autophagy-like vesicle import.  Under stress 
or nutritional deprivation, cells use autophagy as a catabolic mechanism for recycling 
cellular materials that can be redistributed (32,33).  Autophagy, specifically 
macroautophagy, involves engulfment of isolated cytoplasmic constituents within 
double-membraned vesicles, known as autophagosomes (Figure 7).  Autophagosomes 
may fuse with lysosomes, thereby forming autophagolysosomes, and ultimately the 
cargo is  degraded by lysosomal enzymes (34). Employed in these processes of 
autophagosome formation, delivery, and lysosomal fusion are several crucial 
autophagy-related proteins (ATGs) (35).   
Studies have indicated a potentially significant link between lysosomal glycogen 
degradation and autophagy.  In one such study, ‘glycogen autophagy’ is described in the 
livers of newborn infants (36).  Prenatal glycogen accumulation is utilized via lysosomal 
degradation as the primary energy source immediately postnatal before gluconeogenic 
processes have fully developed.  In another study, Pompe disease (PD) mouse models 
(Gaa-/-) show massive accumulation of lysosomal glycogen, as well as a significant 
increase in the number and size of glycogen-containing autophagosomes, an occurrence 
known as ‘autophagic build-up’ (37).  Raben et al (38) have created Gaa-/- mouse 
models with skeletal muscle-specific deficiency of autophagy-related protein 7 (Atg7); 
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results showed reduced skeletal muscle autophagic build-up in the animals, but 
worsened overall clinical phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Autophagy.   Schematic representation of macroautophagy.  Specific 
cytoplasmic constituents, for example a mitochondrion, are engulfed by a lipid double 
membrane, into which microtubule associated protein 1 light chain 3 (LC3-1) is 
incorporated, thereby forming the autophagosome.  The autophagosome fuses to and 
transfers contents into a lysosome, thus forming an autophagolysosome, wherein cargo 
is degraded by lysosomal enzymes.  Adapted from “Lafora Disease: Mechanisms 
Involved in Pathogenesis” by Punitee Garyali, 2014. 
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Pompe disease (PD), also called glycogen storage disease type II (GSDII), is a rare 
metabolic myopathy caused by loss of acid α-glucosidase (GAA), the lysosomal enzyme 
responsible for breaking glycogen down into glucose within lysosomes via glyosidic bond 
cleavage (39).  The hallmark pathology of this disease is massive accumulation of 
lysosomal glycogen, and as such, PD is classified as a ‘lysosomal storage disease’ (LSD) 
(39,40).  Glycogen accumulation has also been detected in autophagosomes and late 
endosomes, which is referred to as ‘autophagic buildup.’  In PD patients, lysosomal 
glycogen accumulation occurs in several tissue types, though cardiac and skeletal tissues 
predominantly contribute to clinical manifestation.   Primary symptoms include muscle 
weakness, hypotonia, cardiac hypertrophy, and cardiomyopathy.  In milder, later-onset 
adult PD cases, GAA enzyme activity is reduced by about 80-90%, and death is often 
attributed to respiratory failure.   In the more severe, infantile PD cases, GAA enzyme 
activity is reduced by 98-99%, and death due to hypertrophic cardiomyopathy usually 
occurs within the first year of life (31,41).  Analyses of Gaa-/- mouse models reveal heart 
sizes up to three times larger than normal (42), which is due in large part to markedly 
increased left ventricular wall thickness (43).  As demonstrated by Douillard-Guilloux et 
al (44), PD-related heart failure is likely directly related to the massive glycogen 
accumulation within the cells of heart tissue.  In this study, Gaa-/- mice were 
intercrossed with glycogen synthase 1 knockout mice (Gys1-/-) to generate a new 
double-knockout model (DKO).  The DKO animals showed significantly reduced levels of 
glycogen in the heart and skeletal muscle, and reduced lysosomal distension and 
autophagic build-up, as well as complete reversal of cardiomegaly.   Furthermore, this 
13 
 
Gaa-/-  Gys1-/- mouse model also exhibited improved glucose metabolism and insulin 
tolerance.  
The only treatment currently available for PD is enzyme replacement therapy 
(ERT), which involves intravenous infusion of a recombinant human GAA (rhGAA; 
alglucosidase alfa, Myozyme®, Genzyme Corporation, Framingham, MA) to counteract 
the endogenous deficiency. ERT has been less successful in PD, however, due to 
inefficient delivery of the recombinant enzyme to the lysosomes of certain target 
tissues, in particular skeletal muscle (45).  Furthermore, these treatments are expensive 
and must be administered continuously throughout the life of the patient.  As such, 
there is a significant need for improvement in Pompe disease therapy. 
 
4. Lafora Disease 
First characterized in 1911 by Spanish neurologist Gonzalo Lafora, Lafora 
progressive myoclonus epilepsy, or Lafora disease (LD), is a fatal neurodegenerative 
disease characterized by deposits of aberrantly branched glycogen, called polyglucosan, 
and some associated proteins (46) (Figure 8). These dense inclusions were later named 
‘Lafora bodies’ (47) and have been detected microscopically in several tissue types, 
including skeletal muscle, neuron, and heart (46,48).  In adolescence, LD manifests as 
myoclonus, epilepsy, and neurodegeneration, and as the disease progresses, the patient 
generally enters a vegetative state and dies due to respiratory failure within a decade 
(49,50).  This disease is very rare and occurs more often in areas of the world where 
consanguinity is common. 
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Lafora disease is primarily caused by mutation of either the gene encoding 
laforin, EPM2A (23,51), or malin, EPM2B (52).  The resultant disease phenotype of 
EPM2A mutation is indistinguishable from that of EPM2B mutation (53); however, 
patients with EPM2B mutations experience later onset of symptoms and slower disease 
progression (54).  To link Lafora body formation with Lafora disease pathology, Epm2a-/- 
mice were crossed with Ptg-/- mice (55),  thereby generating an LD mouse model 
deficient in PTG, a critical activator of glycogen synthesis via regulation of glycogen 
synthase (see section 8).  This resulted in near complete alleviation of molecular LD 
pathogeneses; the double knockout mice had almost no Lafora bodies, no 
neurodegeneration, and no seizures. Echocardiographic analyses of both Epm2a-/- and 
Epm2b-/- mice indicate no significant impairment of cardiac function (56).   
 
5.  Laforin  
Encoded by EPM2A, laforin is a ubiquitous, glycogen phosphatase most highly 
expressed in the skeletal muscle, liver, kidneys, heart, and brain (57,58).  Laforin 
contains both an N-terminal carbohydrate-binding (CBM20) module and a catalytic C-
terminal atypical dual-specificity phosphatase domain within the same polypeptide.  In 
accordance with this architecture, recombinant laforin binds to complex polysaccharides 
(59,60), and in addition, laforin has been shown in vitro to remove the phosphate that 
was incorporated during synthesis from both glycogen (9) and amylopectin (62).   
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Figure 8. Lafora Bodies. An electron micrograph depiction of a Lafora body 
in a neuropil of an Epm2a-/- mouse. Courtesy of Cameron Ackerley, The 
Hospital for Sick Children, University of Toronto. 
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While trace amounts of phosphate are found in normal glycogen, both Epm2a-/- 
(7,8) and Epm2b-/- (61,62) (see section 6) mice exhibit hyperphosphorylated glycogen, 
which results in structural abnormalities consistent with Lafora body formation as the 
mice age.  These results indicate that laforin functions as a glycogen phosphatase in 
vivo.  Around 60 disease-causing mutations have been identified within EPM2A, and 
nearly all result in a defect of either the phosphatase or carbohydrate binding activities 
of laforin (The Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism 
Database; http://projects.tcag.ca/lafora/).  Malin and laforin have been implicated in 
glycogen metabolism as well as quality control via protein degradation, the autophago-
lysosomal pathway, the ubiquitin-proteasomal pathway, and the ER stress response 
pathway (63-65).  Furthermore, laforin has also been shown to bind to several of the 
enzymes involved in glycogen metabolism: glycogen synthase, GSK3, PTG, and malin 
(66-68).  It has been proposed that laforin senses cytosolic glycogen accumulation, and 
subsequently alters its own cellular levels, as necessary (69).  Although the specific 
details of these functions and interactions are unclear, it is now widely accepted that 
laforin acts as a glycogen phosphatase. 
 
6.  Malin  
EPM2B (also known as NHLRC1) is located on chromosome 6q22.3 and contains only 
one exon, which encodes the 395 amino acid polypeptide known as malin. It consists of 
a RING finger characteristic of E3 ubiquitin ligases and 6 NHL domains involved in 
protein-protein interactions (52).  Interspersed throughout the EPM2B gene, in both the 
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RING finger and NHL domains, are nearly 60 disease-causing mutations and 
polymorphisms (The Lafora Progressive Myoclonus Epilepsy Mutation and 
Polymorphism Database; http://projects.tcag.ca/lafora/).  
From in vitro and overexpressing cell culture systems, EPM2B has been proposed 
to ubiquitinate enzymes involved with glycogen metabolism, including laforin (68), 
glycogen synthase (GS) (70), protein targeting glycogen (PTG) (68,70), and glycogen 
debranching enzyme (AGL) (71).  If ubiquitination by malin served to target any of these 
proteins for degradation, it could be expected that malin deficiency would increase 
these proteins levels in vivo.  In Epm2b-/- mice, however, it was found that the levels of 
each these proteins remained unchanged, except laforin, which was increased (72).  
Increased levels of laforin have also been detected in human Lafora disease patients 
with EMP2B mutations (73).  While malin deficiency may be preventing degradation of 
laforin, it has also been proposed that laforin is simply binding to and being sequestered 
by abnormal glycogen, thus prohibiting its degradation (74).  In fact, in malin-deficient 
mice, genetic depletion of PTG (see section 8) reduced glycogen production and almost 
completely eliminated Lafora bodies (75).  In addition to resolving the 
neurodegeneration, myoclonus, seizure susceptibility, and behavioral abnormality, 
laforin levels were also normalized (DePaoli-Roach et al, unpublished results) arguing 
against the idea that laforin is a malin substrate.  Similar results were also reported in 
studies of specific deletion of glycogen synthase in the brain tissue of mice (76). While 
much remains to be understood regarding malin’s exact function, downregulation of 
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glycogen synthesis seems to be a potential therapy for both malin and laforin 
deficiency-linked Lafora disease. 
 
7. Stbd1 
Starch binding domain containing protein 1 (Stbd1, also known as GENX 3414 
and genethonin 1) is highly expressed in the primary glycogen-storing tissues, heart, 
liver, and skeletal muscle (21,77,78).  The N-terminus of Stbd1 enables membrane 
association via a highly conserved 24-residue hydrophobic sequence, while the C-
terminus contains a carbohydrate-binding CBM20 domain (18,21,77,78).  Stbd1 binds 
preferentially to less-branched polysaccharides, such as the glycogen isolated from 
Lafora disease mouse models (21).   
Although the exact function of Stbd1 is unknown, recent studies suggest that 
Stbd1 plays a role in glycogen metabolism, functioning as tether for glycogen to 
subcellular membranes (21).  Additionally, studies using glycogen-deficient mice 
(glycogen synthase knockouts, Gys1-/-) indicate that Stbd1 levels are significantly 
decreased.  Together these results suggest an important link between Stbd1 and the 
intracellular trafficking and disposal of aberrantly-structured glycogen.  In another study 
using Pompe disease mice with abnormal glycogen accumulation, Stbd1 levels were 
quantified and shown to be elevated (79).  Suppression of Stbd1, however, did not 
significantly attenuate lysosomal glycogen accumulation, and as such, the authors 
conclude that Stbd1 is not a likely therapeutic target for PD.  
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8. PTG 
Encoded by the PPP1R3C gene, protein targeting glycogen (PTG) is expressed 
primarily in insulin-sensitive tissues and serves as a scaffolding protein that facilitates 
localization of protein phosphatase-1 (PP1) to glycogen (80).  PP1 plays a central role in 
glycogen synthesis and is composed of a catalytic subunit responsible for 
dephosphorylation of proteins and a regulatory subunit responsible for 
compartmentalization and determination of substrate specificity.  This enzyme 
enhances glycogen synthesis via glycogen synthase activation, while inhibiting glycogen 
breakdown via deactivation of phosphorylase kinase and glycogen phosphorylase. 
 In a previous study, disruption of PPP1R3C was reported to be embryonic lethal 
(81).  In contrast, however, is more recent work by DePaoli-Roach et al, in which a PTG-
deficient mouse line was generated and found to be healthy with no obvious defects. 
These observations are supported by the studies demonstrating that crosses of  Ptg-/- 
mice with either Epm2a-/- or Epm2b-/- mice result in healthy, viable double knockout 
animals (62,75).    
 
9. Mouse Model of Pompe Disease 
Genotypically and phenotypically accurate PD mouse models deficient in 
lysosomal acid α-glucosidase were generated as previously described by Raben et. al 
(82).   The Gaa-/- mice possess characteristics of both infantile and adult PD.  The 
animals develop cardiomegaly, cardiomyopathy, and skeletal muscle myopathy, while 
other symptoms, such as muscle wasting, manifest relatively late at around 7 – 9 
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months of age (83).  Gaa-/- mice survive up to 1.5 years and accurately recapitulate the 
biochemistry of the disease.  As such, this mouse model is suitable for further 
investigation of the pathophysiology of and novel therapies for Pompe disease. 
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RESEARCH OBJECTIVE 
The primary aim of this study is to determine the molecular effect of four specific 
genetic knockouts, Epm2a, Epm2b, Stbd1, and Ptg, on total glycogen load in the heart 
tissue of Pompe disease mouse models.  We opted for examination of the heart, as in 
severe infantile PD, it is accumulation of glycogen in this tissue that results in mortality 
due to hypertrophic cardiomyopathy.  Malin and laforin were selected for this study 
with the hypothesis that their absence might reduce autophagy, which consequently 
could also decrease lysosomal glycogen importation and accumulation.  Stbd1 was 
chosen with the rationale that its deficiency might disable glycogen transport into 
lysosomes, thereby alleviating the major pathology of Pompe disease.    Lastly, PTG was 
selected in light of the previously described success of PTG deficiency in abrogating 
Lafora body formation in LD mouse models (55,75).  Glycogen levels were examined in 
the hearts of wildtype (WT), single knockout, and double knockout mice in a Gaa-/- 
background. 
 
 
 
 
 
 
 
 
22 
 
EXPERIMENTAL PROCEDURES 
1. Maintenance of Mice 
The Pompe disease mouse model (Gaa-/-) used to generate the mouse lines in 
this study was obtained from the laboratories of Dr. Nina Raben at the National Institute 
of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (82).  The malin and laforin 
deficient (Epm2a-/- and Epm2b-/-) mice have been described previously (56,73,84).  The 
Stbd1 deficient mice (Stbd1-/-) were recently generated (unpublished results) in the 
laboratory of Dr. Peter Roach, Department of Biochemistry and Molecular Biology at 
Indiana University School of Medicine.  The PTG deficient mice (Ptg-/-) were generated 
in the laboratory of Dr. Anna Depaoli-Roach in the Department of Biochemistry and 
Molecular Biology at Indiana University School of Medicine (74). The Gaa-/- mice were 
intercrossed with the Epm2a-/-, Epm2b-/-, Stbd1-/-, and PTG-/- mice to generate 
wildtype, single knockout, and double knockout mice. 
All mice used in this study were maintained in temperature and humidity-
controlled environments with a 12:12-hour light-dark cycle, fed a standard murine diet 
(Harlan Teklad global diet 2018SX), and allowed food and water ad libitum.  After 
weighing, 10-12 month-old male animals were sacrificed by cervical dislocation.  Heart 
tissue was harvested, transferred immediately into liquid nitrogen, stored at -80°C, and 
weighed at a later time.  All studies were conducted in strict accordance with Federal 
Guidelines, and all protocols were approved by the Institutional Animal Use and Care 
Committee of Indiana University School of Medicine. 
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2. Measurement of Glycogen Levels in Tissue Samples 
Total glycogen in the heart tissue samples was quantified following the protocol 
developed by Suzuki et al (85).  Approximately 30mg of powdered heart tissue was 
measured into a 1.5 mL screw cap tube and 300μL of boiling hot, freshly prepared     
30% KOH was added.  The tissue was boiled for 30 minutes, mixing by inversion every   
5-10 minutes. The samples were cooled on ice, and then 100μL of 2% Na2SO4 (w/v), 
10μL of 1M LiCl, and 800μL of 100% ethanol were added.  The samples were incubated 
at -20°C overnight to precipitate the glycogen.  
After precipitation, the glycogen was collected by centrifugation at 14,000rpm at 
4°C for 20 minutes, dried for 10 minutes in a SpeedVac, resuspended in 100μL of water, 
precipitated again by addition of 10μL of 1M LiCl and 800μL of 100% ethanol, and 
incubated at -20°C for 1 hour. This procedure was repeated one more time, and the 
samples were kept at -20°C overnight.  
Following the third precipitation, the glycogen pellet was digested enzymatically 
overnight in a 40°C water bath with 100μL of amyloglucosidase diluted in 0.2 mM 
sodium acetate pH 4.8 to give a final concentration 0.3mg/ml.  Following the digestion, 
the samples were centrifuged at 14,000rpm for 5 minutes, and the supernatant was 
transferred to a new tube.  The amount of glucose was determined by a coupled 
reaction: conversion of glucose to glucose-6-phoshate by hexokinase and reduction of 
nicotinamide adenine dinucleotide phosphate (NADP+) to nicotinamide adenine 
dinucleotide phosphate (NADPH) by glucose-6-phosphate dehydrogenase (G6PDH) (86).   
Unless a dilution was needed, 10μL of digested glycogen was added to 300μL of assay 
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buffer (300mM triethanolamine pH 7.6, 4mM MgCl2, 0.9mM NADP
+, 2 mM ATP, and 
2μg/mL glucose-6-phosphate dehydrogenase (Roche)).  From this mixture, 100μL was 
taken from each tube, and using a spectrophotometer, the absorbance was read at 
340nm and recorded to quantify the inference of background absorption in the samples.  
Then, 5μL of hexokinase (1 mg/mL stock, Roche) (diluted 1:10 in 3.2M (NH4)2SO4) was 
added to the remaining 200μL, and the samples were incubated at room temperature 
for 30 minutes. The absorbance was read and recorded at 340nm again to determine 
the concentration of NADPH, which is directly related to the glucose produced by the 
digestion of glycogen.  The difference between the two spectrophotomic values, the net 
absorption, was used to calculate glucose equivalents based on a molar extinction 
coefficient for NADPH of 6.22 x103.  Glycogen content is expressed as μmol of 
glucose/mg of tissue. 
 
3. Statistical Analysis 
 The data are presented as the mean ± SEM for the indicated number of animals.  
Statistical significance was determined by an unpaired Student’s t-test and was 
considered significant at p < 0.05. 
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RESULTS 
 Accumulation of lysosomal glycogen, the hallmark of Pompe disease, occurs in 
the Gaa -/- mouse models of the disease.  To determine the effects laforin, malin, Stbd1, 
and Ptg deficiencies on glycogen levels in PD mouse models, we analyzed the heart 
glycogen content of wildtype (WT), single knockouts, and double knockouts.  Hearts 
samples were harvested from the animals and glycogen was determined as described in 
the experimental procedures.   Five different mice were assayed for every genetic 
combination. 
  In the first experiment, depicted in Figure 9, we quantified glycogen levels in the 
heart of Epm2a-/- and Gaa-/- mouse crosses.  The glycogen levels of the Gaa+/+    
Epm2a+/+ (wiltype or WT), Gaa+/+    Epm2a-/- (laforin single knockout or LKO), Gaa-/-    
Epm2a+/+ (Gaa single knockout or GKO), and Gaa-/-   Epm2a-/- (Gaa and laforin double 
knockout or GLKO) groups were 1.93±0.58, 11.24±3.60, 197±3.74, and 190±7.98µmol 
glucose/gram tissue, respectively.  The LKO group had 5-fold higher glycogen levels than 
the WT, and this difference reached statistical significance (p = 0.034).  The GKO had 
approximately 100-fold higher glycogen content than the WT (p = 2.2E-11), thus also 
reaching statistical significance.  Likewise, the GLKO group had around 90-fold higher 
glycogen levels than the WT, a difference which was statistically significant (p = 1.2E-8).  
The GLKO group had approximately 4% less glycogen than the GKO, however this 
difference was not significant (p = 0.41).   
Figure 10 depicts the results of the second experiment, wherein we quantified 
glycogen levels in hearts of Epm2b-/- and Gaa-/- mouse crosses.  The glycogen levels of 
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the Gaa+/+    Epm2b+/+ (wiltype or WT), Gaa+/+    Epm2b-/- (malin single knockout or 
MKO), Gaa-/-    Epm2b+/+ (Gaa single knockout or GKO), and Gaa-/-   Epm2b-/- (Gaa and 
malin double knockout or GMKO) groups were 3.43±0.51, 7.44±1.35, 259±15.2, 
266±20.5 µmol glucose/gram tissue, respectively.  The MKO had over 2-fold more 
glycogen than the WT, with the difference in values being statistically significant (p = 
0.028).  With a difference also reaching statistical significance, the GKO group had 
around 75-fold higher glycogen content than the WT (p = 1.6E-7).  The GMKO group 
glycogen levels as compared to the WT were approximately 80-fold greater, which was 
also statistically significant (p = 1.3E-6).  The difference in glycogen levels between the 
GKO and GMKO groups was not of statistical significance (p = 0.76).   
In the third experiment, we quantified glycogen levels in heart samples from the 
Stbd1-/- and Gaa-/- mouse crosses; these results are shown in Figure 11. The glycogen 
levels of the Gaa+/+    Stbd1+/+ (wildtype or WT), Gaa+/+    Stbd1-/- (Stbd1 single 
knockout or SKO), Gaa-/-    Stbd1+/+ (Gaa single knockout or GKO), and Gaa-/-   Stbd1-/- 
(Gaa and Stbd1 double knockout or GSKO) groups were 2.86±0.60, 3.79±0.60, 
205.3±20.91, and 196.2±16.15 µmol glucose/gram tissue, respectively.  The SKO group 
had approximately 32% more glycogen than the WT, though the difference in values 
was not significant (p = 0.31).  The glycogen content of both the GKO and the GSKO 
groups was about 70-fold higher than the WT, and both differences were statistically 
significant (p = 1.1E-5 and p = 2.2E-6, respectively).  The GSKO group had slightly lower 
glycogen levels than the GKO, though the difference was not statistically significant        
(p = 0.74).   
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Figure 12 depicts the results of the final experiment, in which we quantified 
heart tissue glycogen levels in mice derived from crosses between Ptg-/- and Gaa-/- 
animals.  The glycogen levels of the Gaa+/+    Ptg+/+ (WT), Gaa+/+    Ptg-/- (PKO), Gaa-/-    
Ptg+/+ (GKO), and Gaa-/-   Ptg-/- (GPKO) groups were 2.86±0.92, 1.37±0.30, 
215.3±12.17, and 196.2±6.06µmol glucose/gram tissue, respectively.  Although the PKO 
group had more than 50% less glycogen content than the WT, the difference in values 
did not reach statistical significance (p = 0.19).  This lack of statistical significance is likely 
due to a high SEM, and it is quite possible that increasing the number of animals might 
result in differences of statistical significance. The GKO group had approximately 75-fold 
greater glycogen content than the WT, and the difference was found to be of statistical 
significance (p = 1.2E-7).  Similarly, the glycogen levels in the GPKO group were 
statistically significantly higher, by nearly 70-fold, than the WT (p = 1.1E-9).  The GPKO 
was found to have slightly less glycogen than the GKO, though the difference was not 
statistically significant (p = 0.20). 
Heart to body weight ratios (H/BW, see Figure 13) were used to determine the 
relative degree of cardiac hypertrophy among wildtype, single knockout, and double 
knockout mice for each group.  The H/BW was calculated as milligrams of heart tissue 
per gram of body weight.  Across all Gaa-/- groups, high glycogen levels are strongly 
correlated with the development of cardiomegaly.   In comparisons of H/BWs in the 
laforin group, there were no statistically significant differences between the Gaa+/+  
Epm2a-/- (LKO) and Gaa+/+  Epm2a+/+ (WT) groups (p = 0.53) or between the Gaa-/-  
Epm2a-/- (GLKO) and Gaa-/-  Epm2a+/+ (GKO) groups (p = 0.97).    The H/BWs of both 
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the GKO and the GLKO groups were nearly 2-fold greater than the WT, and both of 
these differences were statistically significant (p = 6.4E-4 and p = 2.0E-4, respectively).  
Comparison of the H/BW of GLKO to the GKO groups did not result in a difference of 
statistical significance (p = 0.97).   
In the malin group, it was found that the MKO group had a very slightly higher 
H/BW than the WT group, 4.0 versus 3.7, respectively, and although slight, this 
difference reached statistical significance (p = 0.044).  Both the GKO and GMKO 
exhibited elevations in H/BW of statistical significance as compared to the WT; these 
elevations were 2- fold (p = 7.7E-5) and 1.8-fold (p = 1.1E-4), respectively.  Although the 
H/BW of the GMKO group was lower than that of the GKO, the difference was not of 
statistical significance (p = 0.38).   
Next, in the Stbd1 group, the SKO group had an approximately 10% lower H/BW 
than the WT group, but the reduction was not of statistical significance (p = 0.29).  The 
H/BWs of both the GKO and GSKO groups were statistically significantly higher, about   
2-fold, than that of the WT (p = 3.1E-4 and p = 3.1E-5, respectively).  Comparison of the 
GSKO to the GKO group did not reveal a statistically significant difference in H/BW (p = 
0.60).   
Finally, in the PTG group, it was found that although the PKO group exhibited a 
nearly 10% reduction in H/BW as compared to the WT, the difference was not of 
statistical significance (p = 0.24).  The GKO and GPKO groups demonstrated increases of 
1.6-fold and 1.4-fold, respectively, in H/BW as compared to the WT group, and both of 
these differences were of statistical significance (p = 4.8E-4 and p = 3.9E-3, respectively).  
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Lastly, the GPKO group exhibited an approximately 10% reduction in H/BW as compared 
to the GKO group, but the difference was not statistically significant (p = 0.17). 
Echocardiography (data not shown) was also performed.  None of the analyses 
of the Gaa-/- mice revealed significant defects in cardiac function, including cardiac 
output, ejection fraction, and fractional shortening, among other parameters.  The 
primary difference of statistical significance detected in the Gaa-/- mouse hearts as 
compared to the WT was increased posterior and anterior left ventricular wall thickness.  
Comparison of the Gaa-/- single knockout groups (Epm2a+/+   Gaa-/-, Epm2b+/+       
Gaa-/-, Stbd1+/+   Gaa-/-, and Ptg+/+   Gaa-/-) to the double knockout (DKO) groups, 
however, did not result in differences of statistical significance.  These observations are 
in accordance with the H/BW results; the difference between the GKO and DKO groups 
was in no case found to be of statistical significance. 
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Figure 9. Glycogen in Heart Tissue from Mice Lacking Acid α-Glucosidase and 
Laforin.   Glycogen levels in  Gaa+/+    Epm2a+/+ (WT), Gaa+/+    Epm2a-/- 
(LKO), Gaa-/-    Epm2a+/+ (GKO), and Gaa-/-   Epm2a-/- (GLKO), were 
analyzed.  Levels are expressed as glucose equivalents per gram of tissue.  
Values represent one assay for the GKO and GLKO groups and the average of 
two repeat assays for the WT and LKO groups ± SEM.  Each group consisted of 
5 mouse hearts (n=5).   Values marked by the same letter are not statistically 
significant; the different letters indicate p<0.05. 
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b 
c c 
   WT     LKO      GKO        GLKO 
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Figure 10. Glycogen in Heart Tissue from Mice Lacking Acid α-Glucosidase and 
Malin.   Glycogen levels in  Gaa+/+    Epm2b+/+ (WT), Gaa+/+    Epm2b -/- (MKO), 
Gaa-/-    Epm2b +/+ (GKO), and Gaa-/-   Epm2b -/- (GMKO), were analyzed.  Levels 
are expressed as glucose equivalents per gram of tissue.  Values represent one 
assay for the GKO and GMKO groups - and the average of two repeat assays for 
the WT and MKO groups ± SEM.  Each group consisted of 5 mouse hearts (n=5).  
Values marked by the same letter are not statistically significant; the different 
letters indicate p<0.05. 
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Figure 11. Glycogen in Heart Tissue from Mice Lacking Acid α-Glucosidase and Starch 
Binding Domain 1.   Glycogen levels in  Gaa+/+    Stbd1+/+ (WT), Gaa+/+    Stbd1-/- 
(SKO), Gaa-/-    Stbd1+/+ (GKO), and Gaa-/-   Stbd1-/- (GSKO), were analyzed.  Levels 
are expressed as glucose equivalents per gram of tissue.  Values represent one assay 
for the GKO and GSKO groups and the average of two repeat assays for the WT and 
SKO groups ± SEM. Each group consisted of 5 mouse hearts (n=5).  Values marked by 
the same letter are not statistically significant; the different letters indicate p<0.05. 
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   WT     SKO      GKO       GSKO 
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Figure 12. Glycogen in Heart Tissue from Mice Lacking Acid α-Glucosidase and 
Protein Targeting to Glycogen.   Glycogen levels in  Gaa+/+    Ptg+/+ (WT), 
Gaa+/+    Ptg-/- (PKO), Gaa-/-    Ptg+/+ (GKO), and Gaa-/-   Ptg-/- (GPKO), were 
analyzed.  Levels are expressed as glucose equivalents per gram of tissue.  Values 
represent one assay for the GKO and GPKO groups and the average of two repeat 
assays for the WT and PKO groups ± SEM.  Each group consisted of 5 mouse 
hearts (n=5).  Values marked by the same letter are not statistically significant; 
the different letters indicate p<0.05. 
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Figure 13. Heart to Body Weight Ratio in Mice Lacking Acid α-Glucosidase and 
Laforin, Malin, Starch Binding Domain 1, or Protein Targeting to Glycogen.   Heart 
to body weight ratios were calculated and are expressed here as milligrams of heart 
tissue per gram of body weight.  Values represent the average of five mouse hearts 
for each group, depicted ± SEM.  Values marked by the same letter are not 
statistically significant; the different letters indicate p<0.05. 
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DISCUSSION 
The hallmarks of Pompe disease, the substantial lysosomal glycogen 
accumulation and autophagic build-up, are reportedly the basis of the disease’s 
pathologies (44) and likely also the cause of the fatal cardiomyopathy observed in 
severe, infantile PD cases (31,41).   The aberrant lysosomal glycogen metabolism is the 
result of a genetic defect in acid α-glucosidase (GAA), the enzyme responsible for 
breaking down glycogen to glucose within the lysosomes (39).  Although PD is an 
extremely rare disease, it can be fatal within the first year of life in severe cases and as 
such requires additional study and development of improved therapies.  Pompe disease 
is currently being treated with enzyme replacement therapy (ERT), though 
unfortunately, the clinical success of ERT in PD patients has been seriously limited.  
Patients with severe infantile PD, who have received ERT, experience markedly 
improved cardiac function and lifespan (87,88) but at the cost of chronic, permanent 
disabilities, including devastating skeletal muscle myopathy, osteopenia, hearing loss, 
and severe gastroesophageal reflux (89-91).  Recent success of substrate reduction 
therapy (SRT) in other lysosomal diseases (92) has stimulated interest in the possible 
application of SRT in Pompe disease treatment.  Using primary myoblasts from Gaa-/- 
mice, inhibition of the major glycogen synthesis enzyme, glycogen synthase (GYS1), 
resulted in reduced cytosolic and lysosomal glycogen levels, as well as reduced 
lysosomal size and number (93).   Further studies with the Gys -/-   Gaa-/- mice indicated 
normalized cardiac function, glycogen storage, autophagy, and exercise capacity (44).  
However, as GYS1 deficiency in results in a 90% death rate of mouse pups at birth due 
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to cardiac impairment (94),  total GYS1 suppression may not be of utility in Pompe 
disease therapy.  Partial inhibition, on the other hand, may yet be considered as 
possible a therapeutic approach.   
In this study, we sought to characterize the effects of laforin, malin, Stbd1, and 
Ptg deficiencies on overall glycogen levels in heart tissue from Gaa-/- mice in hopes of 
identifying a protein deficiency that may attenuate classic PD glycogen accumulation-
linked cardiomyopathy.  We postulated that the defects in autophagy observed in malin 
and laforin deficient mice, may consequently reduce lysosomal glycogen import and 
accumulation.  However, neither Gaa -/-   Epm2a-/- (GLKO) mice nor Gaa -/-   Epm2b-/- 
(GMKO) mice exhibited significantly reduced glycogen levels in the heart tissue as 
compared to the single Gaa-/- knockout (GKO) mice.  Though both Gaa+/+  Epm2a-/- 
(LKO) and Gaa+/+  Epm2b-/- (MKO) mice exhibited significantly elevated glycogen levels 
as compared to the WT, this increase is likely in cytosolic glycogen rather than the 
lysosomal.  While it is possible that laforin and malin do not affect how glycogen is 
trafficked to and accumulated within lysosomes in Pompe disease, these proteins may 
yet play some undetermined role, and should thus not be altogether ruled out.    
Stbd1 deficiency was postulated to impair glycogen transport into lysosomes, 
thereby mitigating the primary pathology of Pompe disease.  We did not, however, find 
a statistically significant reduction of glycogen levels  in Gaa -/-  Stbd1-/- (GSKO) mouse 
hearts as compared to  Gaa -/-  Stbd1+/+ (GKO) hearts.  These results are in accordance 
with another study, which conclude that Stbd1 is not a probable candidate for Pompe 
therapy research (79).   
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Lastly, Ptg-/- mice were analyzed, as previously PTG deficiency in both Epm2a-/- 
and Epm2b -/- mice resulted in significant reduction of glycogen levels as well as 
abrogation of both Lafora bodies and neurological disorders.  Our rationale was that a 
decrease in glycogen synthesis may also reduce lysosomal accumulation of glycogen in 
Gaa-/- mice.  In this study however, we did not detect a statistically significant decrease 
in the glycogen levels of the Gaa-/-   Ptg-/- (GPKO) hearts as compared to the Gaa-/-   
Ptg+/+ (GKO) hearts. 
In conclusion, analyses of Epm2a-/-, Epm2b-/-, Stbd1-/-, and Ptg-/- in a Gaa-/- 
mouse model background did not reveal reductions of statistical significance in either 
heart tissue glycogen levels or cardiac hypertrophy.  However, in the laforin and malin 
groups, the sum glycogen content of the LKO or MKO and GKO groups was not obviously 
equal to that of the DKO groups.  Inability to detect additivity between these groups 
may be due to the standard error.  Another possibility is that these mouse heart cell 
have simply reached maximum glycogen capacity; the Gaa-/- hearts had over 100-fold 
higher glycogen levels than the WT.  Alternatively, as Epm2a-/- and Epm2b-/- mice 
exhibit elevated levels of cytosolic glycogen, it is possible that lysosomal glycogen 
content was reduced in the GLKO and GMKO groups; however, the elevation of cytosolic 
glycogen compensated for the reduction of lysosomal glycogen in GLKO and GMKO 
hearts, thereby resulting in the lack of additivity.  In this study, we quantified total 
glycogen levels and did not differentiate between lysosomal and cytosolic glycogen.  In 
the future, these issues could be addressed by isolation of the lysosomes to specifically 
quantify glycogen levels therein, or by histological analyses of heart tissue sections with 
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periodic acid–Schiff (PAS) staining to determine the localization of the glycogen 
accumulation.   
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